Factor VIII, Fibrinogen and Heparin Resistance in COVID-19 Patients with Thromboembolism: How Should We Manage the Anticoagulation Therapy?

Clin Appl Thromb Hemost. 2022 Jan-Dec:28:10760296221087692. doi: 10.1177/10760296221087692.

Authors

Felicio Savioli¹, Maurício Claro¹, Fernando Jose da Silva Ramos¹, Laerte Pastore¹

Affiliation

¹ Critical Care Medicine Department, Hospital Sírio Libanês, Sao Paulo, Brazil.

No abstract available

Publication types

Letter

MeSH terms

Anticoagulants / therapeutic use
COVID-19 Drug Treatment*
Factor VIII / therapeutic use
Fibrinogen
Heparin / therapeutic use
Humans
Thromboembolism* / drug therapy
Thromboembolism* / etiology

Substances

Anticoagulants
Factor VIII
Fibrinogen
Heparin